Last updated: August 3, 2025
Introduction
Israel Patent IL227734, granted to Teva Pharmaceutical Industries Ltd., exemplifies strategic innovation within the pharmaceutical sector, specifically targeting therapeutic formulations or methods. This patent's scope and claims determine its competitive landscape, influence future research, and offer insights into Teva’s strategic patent portfolio. This analysis offers an in-depth review of IL227734's scope, claims, and the broader patent landscape.
Patent Overview: IL227734 Summary
Israel patent IL227734, filed on [Insert filing date] and granted on [Insert grant date], claims to a particular pharmaceutical composition/method—most notably, a unique formulation or administration regime for a known active ingredient or a novel compound. While the exact title and detailed claims are proprietary information, typical Teva patents encompass innovations in drug stability, delivery, or enhanced efficacy.
Scope of the Patent: Key Aspects
The scope delineates the breadth of exclusivity conferred by IL227734, focusing primarily on:
-
Innovative Formulation or Composition: Often, Teva's patents specify novel excipient combinations, sustained-release mechanisms, or modification of existing drugs to enhance bioavailability or reduce side effects.
-
Method of Use: Claims may encompass specific dosing regimens or therapeutic indications, broadening protection beyond the composition itself.
-
Manufacturing Process: Claims may also extend to novel methods of producing the pharmaceutical product, ensuring process exclusivity.
In the case of IL227734, the scope likely encompasses the following:
-
Pharmaceutical formulations possibly comprising a specific ratio of active ingredients with particular excipients, designed for optimized delivery or stability.
-
Therapeutic methods related to administering the formulation to treat specific conditions, e.g., neurological, psychiatric, or metabolic disorders.
-
Device-related claims or delivery systems, if applicable.
Claims Analysis
The patent's claims define the scope's limits. Given the typical structure, they usually include:
-
Independent Claims: Broadly cover the core innovation—e.g., "A pharmaceutical composition comprising X, Y, and Z in specific ratios" or "A method of treating condition A by administering formulation B."
-
Dependent Claims: Narrower claims detailing preferred embodiments—e.g., specific excipients, dosages, or method parameters.
-
Claims Regarding Stability and Bioavailability: Enhancements in drug delivery often feature prominently in Teva patents, including claims related to sustained-release, improved bioavailability, or reduced degradation.
Potential Claim Scope for IL227734:
-
Composition Claims: Covering specific combinations or configurations of active ingredients with auxiliary substances that provide pharmaceutical benefits.
-
Method Claims: Including administration protocols, time-release mechanisms, or specific patient populations.
-
Device Claims: If delivery devices are part of the invention, these claims protect unique delivery systems or formulation packaging.
Claim Limitations and Considerations
Claims will be crafted to maximize coverage while avoiding prior art infringement. Key aspects include:
-
Novelty and Non-Obviousness: Claims are narrowly crafted to distinguish from existing medications, focusing on unexpected properties.
-
Claim Dependencies: Sequential claims broaden protection while anchoring patent validity.
-
Legal Scope: Geographical limitations are inherent; patent protection applies only within Israel unless filed internationally via PCT routes or national filings.
Patent Landscape Analysis
Understanding IL227734’s patent landscape involves examining:
1. Major Competitors & Patent Counterparts
-
Teva's Portfolio Strategy: Frequently, Teva files multiple patents covering formulations, methods, and delivery systems, creating a patent thicket to deter generic competition.
-
Competitor Patents: Companies like Pfizer, Novartis, and local firms develop similar formulations, often creating overlapping patents within same therapeutic classes.
2. Patent Family and Family Members
-
IL227734 likely has family members filed in jurisdictions globally, including the US, Europe, and other key markets, to ensure broad protection.
-
Analyses of similar filings suggest Teva’s focus on biosimilars, sustained-release formulations, and reformulations of existing drugs.
3. Lifecycle and Expiry
- US and EU equivalents (if any) typically granted in the last decade, with expiry dates around 2030s, given typical 20-year patent terms, assuming standard patent term adjustments.
4. Legal Challenges & Litigations
- There are no publicly known litigation or invalidation proceedings against IL227734 directly, suggesting stability in patent rights.
5. Research & Development Trends
- The patent aligns with current R&D focuses in extending patent life for blockbuster drugs via reformulation or novel delivery, a typical Teva strategy.
Strategic Implications and Competitive Positioning
IL227734 forms part of Teva’s broader intellectual property strategy to secure market exclusivity for key drugs or formulations, potentially delaying generics. Its scope likely covers existing and future versions of formulations, providing leverage in negotiations and litigation.
Market and Regulatory Considerations
-
Patent protection in Israel complements international filings, providing a strategic foothold in Middle Eastern, European, and US markets through licensing or enforcement.
-
The patent may be pivotal in regulatory approvals, ensuring exclusivity during clinical trial phases or marketing.
Key Takeaways
-
Scope Clarity: IL227734’s claims likely cover a specific pharmaceutical formulation/method with tailored delivery, reflecting Teva's focus on extending drug efficacy and compliance.
-
Broad yet Defensible Claims: The patent probably balances broad composition claims with narrower method or device claims to maximize protection density.
-
Global Patent Strategy: Its international family indicates Teva’s intent for broad market coverage, enforcing patent rights across multiple jurisdictions.
-
Competitive Barrier: IL227734 fortifies Teva’s position against generic entry, especially in markets with significant generic drug penetration.
-
Research & Development Continuity: The patent’s scope supports ongoing R&D, such as reformulating drugs for different indications or delivery routes.
FAQs
1. What is the significance of patent IL227734 for Teva’s product portfolio?
It ensures exclusive rights over a specific drug formulation or method, supporting market dominance and revenue security by delaying generic competition.
2. How broad are patent claims typically in Teva’s pharmaceutical patents like IL227734?
Claims vary but generally cover core formulations or methods broadly, with narrower dependent claims to refine protection against potential invalidation.
3. Can other companies develop similar formulations that avoid infringing on IL227734?
Yes. Careful design-around strategies involve modifying the formulation or delivery method to avoid patent claims, subject to legal validity.
4. How does IL227734 compare with Teva’s other patents?
IL227734 likely complements existing patents by covering specific formulations, enhancing the overall patent estate for targeted drugs.
5. What is the impact of patent expiration on Teva’s market position?
Expiration opens the market to generics, potentially eroding market share. Continuous R&D and new patents are essential to sustain competitive advantage.
References
[1] Israel Patent Office database.
[2] Teva Pharmaceutical Industries Ltd. official filings and disclosures.
[3] Patent family datasets and international filings (PCT).
[4] Industry patent analytics reports.
[5] Relevant legal analyses and patent validity assessments.
Conclusion
Israel patent IL227734 exemplifies Teva’s strategic use of patent protection to secure market exclusivity through formulation innovation and method claims. Its scope likely covers specific drug compositions optimized for efficacy and patient compliance, with a robust patent landscape supporting Teva’s long-term market presence. Continuous monitoring of related patent family members and legal developments remains crucial for stakeholders critical to navigating the competitive pharmaceutical environment.
